Developer of a drug discovery platform designed to elucidate human biology and create sophisticated therapeutics that at
Developer of a drug discovery platform designed to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases.
Drug Discovery📍 Cambridge, MAFounded 2016
Current Valuation
$525M
as of 2022-Q1
PRIVATE
QL Price
$1.2B
+135% vs last round
QuantLogix's current estimate for LifeMine, published 2026-09-27 — above the last disclosed round of $525M (2022-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$525M
2022-Q1
weight 0.04
Secondary market print
$1.3B
2026-06-27
weight 0.58
This price sits more than 100% away from the last disclosed round. Past a 2× repricing off a single secondary print, the likeliest explanation is that the print and the round describe different share classes rather than a genuine move. It is published and graded like every other price, but treat it with more care.
How this price has held up
No round has priced for LifeMine since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, LifeMine, 2026-09-27 (e00be52ac9916348).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is LifeMine going public?
No. LifeMine is private and has not filed to go public. There is no S-1 on file.
What is LifeMine's valuation in 2026?
LifeMine is valued at $525M as of 2022-Q1, set by its Series C ($175M, Mar 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has LifeMine filed an S-1?
No public S-1 is on file for LifeMine.
How much has LifeMine raised?
LifeMine has raised $300.07M in total, most recently a Series C of $175M in Mar 2022.
Is LifeMine publicly traded — can you buy LifeMine stock?
No. LifeMine is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for LifeMine on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2016
HQ
Cambridge, MA
Employees
51
Total Raised
$300.07M
Last Round
Series C — $175M (Mar 2022)
IPO Status
private
Fundraising Status
Series C · $175M · 4y 6mo ago
privateTotal raised $300.07M
Secondary Market
Implied price / share
$5
Last round price / share
$2.04
vs last round
+145.1%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$175M
Mar 2022
—
$525M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Healthy Volunteers
Latest trial start
2025-04-07
Name-verified against lead sponsor "LifeMine Therapeutics" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for LifeMine as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechnologyLife ScienceTherapeuticsGenetics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.